New Delhi: Kovacocin, developed in collaboration with Bharat Biotech ICMR, has been shown to be 78 per cent effective in preventing covid. The final phase of the experiment was performed on 25,800 people between the ages of 18 and 98.
The vaccine is effective in 78% of cases with mild to moderate symptoms and in 98% of patients with severe symptoms. The number of patients who have been vaccinated has been kept to a minimum. The vaccine is 63% effective against asymptomatic transmission. According to Bharat Biotech, the vaccine has been shown to be 65% effective against the B1.617.2 Delta variant.
COVAXIN® Proven SAFE in India’s Largest Efficacy Trial. Final Phase-3 Pre-Print Data Published on https://t.co/JJh9n3aB6V pic.twitter.com/AhnEg56vFN
– BharatBiotech (haBharatBiotech) July 2, 2021